KROS – keros therapeutics, inc. - common stock (US:NASDAQ)

News

Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a "neutral" rating on the stock.
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% [Yahoo! Finance]
Keros Therapeutics Announces Final Results of Tender Offer [Yahoo! Finance]
Keros Therapeutics Announces Final Results of Tender Offer
Keros Therapeutics Announces Preliminary Results of Tender Offer
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com